Graft versus Host Disease (GvHD) Treatment Market Size, Share and Global Trend By Type (Acute Graft Versus Host Disease (aGvHD), Chronic Graft Versus Host Disease (cGvHD)), By Treatment (mTOR Inhibitors, Tyrosine Kinase Inhibitors, Monoclonal Antibodies, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Regional Forecast, 2024-2032

Graft versus host disease (GvHD) is a condition that occurs after an allogeneic bone marrow or stem cell transplant. Graft versus host disease (GvHD) is a potentially serious disease, which occurs after transplantation with a genetically different individual. Graft versus host disease (GvHD) is classified into two types acute graft versus host disease (aGvHD) and chronic graft versus host disease (cGvHD).

As a recipient of the transplantation process, the individual may be diagnosed with both types, either type or none of the types. Some of the symptoms of the disease include skin rash, gastrointestinal (GI) tract disorders, and others. The individuals or the factors who are at the most risk of being diagnosed with the disease include HLA mismatch, aged recipient, female donor to male recipient and donor lymphocyte infusion.

To gain extensive insights into the market, Request for Customization

Increasing prevalence of graft versus host disease (GvHD), predominantly arising from an increasing number of allogenic transplantations is presenting a large patient pool requiring treatment. This is one of the major factors driving the growth of the global graft versus host disease (GvHD) treatment market.

Also, an increasing number of product approvals for the treatment of graft versus host disease (GvHD) and increased disease diagnosis rate are some of the factors driving the growth of the global graft versus host disease (GvHD) treatment market. According to The Leukemia & Lymphoma Society (LLS), chronic graft versus host disease (GvHD) can occur in 30-70 percent of patients receiving allogeneic transplantation.

The factors limiting the growth of the global graft versus host disease (GvHD) treatment market are the high cost of the treatment and high investment in the clinical trials. According to the studies published by the American Society of Hematology, patients who develop Acute GvHD experience over the US $100,000 more in total healthcare costs-and nearly three additional weeks in the hospital.

Key Players Covered

Some of the major companies that are present in the global graft versus Host Disease (GvHD) treatment market are Genzyme Corporation, Novartis AG, Pfizer Inc., Astellas Pharma Inc., Merck KGaA, Incyte Corporation, and others.

SEGMENTATION 

In 2018, among disease indication, chronic graft versus host disease (cGvHD) dominated the global graft versus host disease (GvHD) treatment market due increasing prevalence and occurrence of the chronic graft versus host disease. This segment is projected to grow at comparatively higher CAGR during the forecast period.

Key Insights

• Prevalence of Graft versus Host Disease, By Key Regions


• Pipeline Analysis


• Recent Industry Developments Such as Partnerships, Mergers, and Acquisitions

Regional Analysis

North America dominated the global graft versus host disease (GvHD) treatment market in 2018. Increasing prevalence of the graft versus host disease in the region is anticipated to drive the growth of the graft versus host disease (GvHD) treatment market. For instance, according to a research study published by the National Center of Biotechnology Information in 2018, suggests that around 30% to 50% of hematopoietic stem cell transplant (HSCT) recipients develop acute GVHD. That interprets to 5500 patients/year who will develop acute graft versus host disease. Eventually, around 50% of patients with acute graft versus host disease have manifestations of chronic graft versus host disease. The graft versus host disease treatment market in Europe is also anticipated to grow at a significant CAGR due to an increased prevalence of cancer, improvements in medical research, and the increasing number of players and research institutes engaged in clinical trials for new drugs/treatment options for GvHD.

Key Industry Developments

• In May 2019, Incyte Corporation received FDA approval for ruxolitinib (Jakafi) for the treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients.
• In February 2016, JCR Pharmaceuticals Co. Ltd., launched mesenchymal stem cell product TEMCELL HS Inj., for the treatment of acute graft versus host disease (aGVHD) in children and adults in Japan. TEMCELL is the first allogeneic cell therapy to be fully approved in Japan.